Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,069 across all filing types
Latest filing 2019-03-19 AGM Information
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
Oasmia Pharmaceutical AB (publ): Press release from the extraordinary general meeting 19 March 2019
AGM Information Classification · 99% confidence The document explicitly discusses an 'extraordinary general meeting' (EGM) where resolutions were passed regarding the election of a new board of directors and their remuneration. It details the outcome of the shareholder vote (election of four members, including the chairman). This content directly relates to the proceedings and results of a shareholder meeting. While it mentions the results of the vote, the primary focus is the announcement of the meeting's decisions, which aligns best with the general scope of shareholder meeting materials. Since the document details the resolutions passed at the EGM, it is most closely related to AGM Information (AGM-R), which covers presentations and materials shared during general meetings, even if this specific one was 'extraordinary'. It is not a DEF 14A (Remuneration Information) as that focuses solely on compensation details, nor is it a DVA (Declaration of Voting Results) which is strictly the tally of votes, although it contains elements of both. Given the context of electing a new board following a request from shareholders, AGM-R is the most appropriate fit for general meeting documentation.
2019-03-19 English
Oasmia Pharmaceutical AB (publ): Kommuniké från extra bolagsstämma den 19 mars 2019
AGM Information Classification · 99% confidence The document is titled "Kommuniké från extra bolagsstämma den 19 mars 2019" (Communication from the Extraordinary General Meeting held on March 19, 2019). It details the decisions made regarding the election of the board of directors (styrelseledamöter) and the chairman (ordförande) during this extraordinary general meeting (extra bolagsstämma). This content directly relates to the outcomes and decisions of a shareholder meeting, specifically concerning board composition. This aligns best with the 'Declaration of Voting Results & Voting Rights Announcements' (DVA), as the election of directors is a primary outcome of a shareholder vote, even if it's not explicitly stating the final vote tally for every resolution, it communicates the result of the election process. It is not an AGM presentation (AGM-R) as it's a communication/press release about the meeting's outcome, nor is it a general management change announcement (MANG) as the context is explicitly a shareholder meeting.
2019-03-19 Swedish
Oasmia Pharmaceutical AB (publ): Press release from the extraordinary general meeting 19 March 2019
AGM Information Classification · 99% confidence The document is explicitly titled 'Press release from the extraordinary general meeting 19 March 2019'. It details resolutions passed regarding the election of a new board of directors and remuneration for those members during this extraordinary general meeting (EGM). This content directly relates to the governance and proceedings of a shareholder meeting, specifically focusing on board composition changes resulting from the meeting. This aligns best with the 'AGM Information' category, even though it is an EGM, as the core subject is the outcome of a general meeting.
2019-03-19 English
Oasmia announces a prospectus regarding admission to trading of new shares
Report Publication Announcement Classification · 98% confidence The document announces that Oasmia Pharmaceutical AB has prepared a prospectus regarding the admission to trading of shares issued in a directed issue. It explicitly states that the Prospectus has been approved by the Swedish Financial Supervisory Authority and is available on the company's website. The document itself is short (3134 characters) and serves primarily to announce the availability and approval of a formal document (the prospectus), rather than being the prospectus or a full financial report. This aligns perfectly with the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing, release, or publication of company reports. It is not a 10-K, IR, or ER, as it is announcing a prospectus related to a capital event, but the *action* described is the publication announcement.
2019-03-18 English
Oasmia announces a prospectus regarding admission to trading of new shares
Share Issue/Capital Change Classification · 95% confidence The document is a press release dated March 18, 2019, titled "Oasmia announces a prospectus regarding admission to trading of new shares." It explicitly states that a prospectus has been approved and is available, and that the shares are expected to be admitted to trading. This document is an announcement about the availability of a formal document (the prospectus) related to a capital change (issuance and admission to trading of new shares). Since the text is short (3390 chars) and announces the publication of a prospectus related to new shares, it strongly suggests a capital/financing update or an announcement of a related document. The core subject is the issuance of new shares and their admission to trading, which falls under 'Capital/Financing Update' (CAP) or 'Share Issue/Capital Change' (SHA). Given the focus on the *prospectus* for the *admission to trading* of *new shares*, 'CAP' (Capital/Financing Update) is highly relevant, as is 'SHA' (Share Issue/Capital Change). However, the document itself is an announcement regarding the prospectus, not the prospectus or the final share issue report. Since it is an announcement about a financing/capital event, and the document is short, it could be considered an RPA if it were just announcing the report. But the content is the substance of the capital change announcement itself (new shares issued, prospectus approved). Comparing CAP and SHA: SHA is for the actual change/issue, CAP is for fundraising/financing activities. The issuance of shares to fund operations is a financing activity. Given the context of a prospectus for admission to trading, 'CAP' is a strong fit for the financing aspect, while 'SHA' covers the share change aspect. Since the document is a press release announcing the prospectus for the admission of new shares, it is fundamentally about a capital structure change. I will classify it as 'CAP' as it relates to the financing mechanism (the prospectus for admission to trading), but 'SHA' is also very close. Given the explicit mention of 'new shares' being issued, 'SHA' (Share Issue/Capital Change) is the most precise fit for the underlying corporate action being announced, even though it's presented via a prospectus announcement.
2019-03-18 English
Oasmia offentliggör prospekt avseende upptagande till handel av nya aktier
Report Publication Announcement Classification · 98% confidence The document is a press release dated March 18, 2019, titled "Oasmia offentliggör prospekt avseende upptagande till handel av nya aktier" (Oasmia publishes prospectus regarding admission to trading of new shares). It explicitly states that a prospectus has been prepared and approved by the Swedish Financial Supervisory Authority (Finansinspektionen) and will be admitted to trading. The document itself is short and serves to announce the publication and availability of the prospectus, rather than being the full prospectus or a comprehensive financial report. This aligns perfectly with the definition of a Report Publication Announcement (RPA), which covers announcements about the release or publication of other company reports/documents. It is not a full 10-K, IR, or ER, but an announcement about a related filing (the prospectus).
2019-03-18 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.